Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

Status unconfirmed · Phase 2

Conditions studied: HIV Infections

In brief

To determine the tolerance and side effects of a combination of lentinan and didanosine (ddI) in comparison with ddI alone. To determine whether the combination of lentinan and ddI produces a significant immunorestorative effect within the study observation period (6-12 months) as measured by an increase in one or more of the following: neutrophil count and activity, T-cell subsets, and a decrease in p24 antigen.

Key facts

Study ID

NCT00002099

Run by

AJI Pharma USA

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have:
• HIV seropositivity.
• Absolute CD4 count of 200 - 500 cells/mm3.
• No active opportunistic infection or Kaposi's sarcoma.
• Prior Medication:
• Allowed:
• Prior ddI for no longer than 3 months.

You may not qualify if…

• Co-existing Condition:
• Patients with the following symptoms or conditions are excluded:
• Lymphoid malignancy.
• Pancreatitis.
• Peripheral neuropathy.
• Critical illness.
• Concurrent Medication:
• Excluded:
• Antiretroviral agents other than ddI.
• Steroids.
• Cytotoxic agents.
• Immunosuppressive agents.
• Immunomodulators.
• 1-Thyroxine.
• Concurrent Treatment:
• Excluded:
• Radiotherapy.
• Prior Medication:
• Excluded within 1 month prior to study entry:
• Antiretroviral agents other than ddI (patients may have received prior ddI for no longer than 3 months total).
• Steroids.
• Cytotoxic agents.
• Immunosuppressive agents.
• Immunomodulators.
• Prior Treatment:

Where it is running

• HIV Research Group — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.